Clinical Trial Update: Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of Hu3F8 (humanized anti-GD2 monoclonal antibody) in combination with GM-CSF for recurrent osteosarcoma, sp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Hu3F8 (Hu3F8)
• Leukine (sargramostim)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Recurrent Osteosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING